SynthesisBMC gastroenterology2022
Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis.
Synthesis in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative Colitis.Inflammatory bowel diseases · 2026Trial
- Comparison of Changes in Biomarkers With Changes in Endoscopic Scores in Patients With Ulcerative Colitis: A Single-Center, Retrospective, Observational Study.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Beyond conventional endoscopy: Image-enhanced techniques in quiescent ulcerative colitis assessment.World journal of gastrointestinal endoscopy · 2026Review
- Treat-to-Target in Ulcerative Colitis: How Soon Is Now?Journal of clinical medicine · 2026Article
- Impact of anti-TNF and anti-IL-12/IL-23 antibody therapy on periodontal inflammation and gingival crevicular fluid IL-6 in patients with inflammatory bowel diseases.Frontiers in immunology · 2026Article
- Development of a tissue-based risk prediction model combining histology and barrier biomarkers for clinical relapse in ulcerative colitis with endoscopic healing.Therapeutic advances in gastroenterology · 2026Article
- The potential of lymphocyte-C-reactive protein ratio upon admission to predict therapeutic responsiveness to mesalazine in adult patients with mild-to-moderate active ulcerative colitis.BMC gastroenterology · 2025Article
- TNF-α Quantification in Formalin-Fixed Paraffin-Embedded Tissues as a Predictive Biomarker in Ulcerative Colitis.Diagnostics (Basel, Switzerland) · 2025Article
- Evaluation of retinal and choroidal structures in patients with ulcerative colitis.International ophthalmology · 2025Article
- Inflammatory Bowel Disease in the Post-STRIDE II Era: Epidemiology and Long-Term Clinical Outcomes from a Population-Based Study.Medical sciences (Basel, Switzerland) · 2025Article
- Fatigue in Patients with Inflammatory Bowel Disease in Remission One Year After Diagnosis (the IBSEN III Study).Journal of Crohn's & colitis · 2025Article
- Histologic healing and clinical outcomes in ulcerative colitis.Intestinal research · 2025Article
- Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition.Intestinal research · 2025Review
- Cell Death-Related Genesets Activity Improved Clinical Concordance and Intrinsically Associated with Alterations in Ulcerative Colitis: Mucosal Healing at Molecular Depth.Journal of inflammation research · 2025Article
- Gastroenterologists' attitudes and challenges toward treat-to-target strategies in inflammatory bowel disease: a multinational survey.Therapeutic advances in gastroenterology · 2025Article
- Drug Optimization in Patients with Mild-to-Moderate Ulcerative Colitis: A Global Survey.Journal of clinical medicine · 2024Article
- Effectiveness of Tofacitinib in Ulcerative Proctitis Compared to Left Sided Colitis and Pancolitis.Digestive diseases and sciences · 2024Article
- Deep mucosal healing in ulcerative colitis: how deep is better?Frontiers in medicine · 2024Review
- Predictive value of serum markers for mucosal healing in patients with inflammatory bowel disease.American journal of translational research · 2024Article
- Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucosal healing (MH) evaluated by endoscopy is a novel target of therapy in UC as it is associated with improved long-term outcomes. It is defined based on the Mayo endoscopic score (MES), but it is still to define whether a value of MES 0 or 1 should be the target. The purpose of this paper is to present the results of a systematic review with meta-analysis which compares long-term outcomes of patients in steroid-free clinical remission with MES 0 with those with MES 1.
methodsA systematic electronic search of the literature was performed using Medline, Scopus, and CENTRAL through December 2020 (PROSPERO n:CRD42020179333). The studies concerned UC patients, in steroid-free clinical remission, with MES of 0 or 1, and with at least 12-months of follow-up.
resultsOut of 4611 citations, 15 eligible studies were identified. Increases in clinical relapse among patients with MES 1 were observed in all the studies included in this review, suggesting that MES of 1 have a higher risk of relapse than a score of 0. MES 0 patients displayed a lower risk of clinical relapse (OR 0.33; 95% CI 0.26-0.43; I
conclusionsMES 0 is associated with a lower rate of clinical relapse than is MES 1. For this reason, MES 0, rather than MES 0-1, should be considered the therapeutic target for patients with UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.